Skip to main
EVAX

EVAX Stock Forecast & Price Target

EVAX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evaxion is currently a clinical-stage biotech company with a promising AI platform, AI-Immunology, that is being leveraged to develop novel vaccines for cancer and infectious diseases. With a strong clinical pipeline and potential future partnerships, Evaxion is well-equipped to bring innovative treatments to patients in the market and generate significant revenue. However, there are inherent risks in the biotech industry, including challenges in technology, clinical trials, regulatory approvals, and competition, which could impact the company's success and financial performance. Investors should also closely monitor the company's updates on its EVX-01 program, which has shown promising results in advanced melanoma and could be a key driver of future partnerships and revenue growth.

Bears say

Evaxion is a clinical-stage TechBio company that aims to develop novel vaccines for cancer and infectious diseases using its AI-Immunology platform. However, their lack of commitment to further development of the GBM personalized cancer vaccine and the uncertainty surrounding their pivot into autoimmune disease therapies raise concerns for potential investors. As a financial analyst, it is important to carefully consider the company's future potential partnerships and licensing strategies before making any investment recommendations.

EVAX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evaxion Biotech A/S (EVAX) Forecast

Analysts have given EVAX a Strong Buy based on their latest research and market trends.

According to 4 analysts, EVAX has a Strong Buy consensus rating as of Apr 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evaxion Biotech A/S (EVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.